AU2017220391B2 - Anti-virus agent and method for treatment of viral infection - Google Patents

Anti-virus agent and method for treatment of viral infection Download PDF

Info

Publication number
AU2017220391B2
AU2017220391B2 AU2017220391A AU2017220391A AU2017220391B2 AU 2017220391 B2 AU2017220391 B2 AU 2017220391B2 AU 2017220391 A AU2017220391 A AU 2017220391A AU 2017220391 A AU2017220391 A AU 2017220391A AU 2017220391 B2 AU2017220391 B2 AU 2017220391B2
Authority
AU
Australia
Prior art keywords
copolymer
acrolein
molecular weight
daltons
previous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017220391A
Other languages
English (en)
Other versions
AU2017220391A1 (en
Inventor
Michele Keryn Dilizia
Graham John Hamilton Melrose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recce Pharmaceuticals Ltd
Original Assignee
Recce Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900595A external-priority patent/AU2016900595A0/en
Application filed by Recce Pharmaceuticals Ltd filed Critical Recce Pharmaceuticals Ltd
Publication of AU2017220391A1 publication Critical patent/AU2017220391A1/en
Application granted granted Critical
Publication of AU2017220391B2 publication Critical patent/AU2017220391B2/en
Priority to AU2023201883A priority Critical patent/AU2023201883B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/78Polymers containing oxygen of acrylic acid or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017220391A 2016-02-19 2017-02-17 Anti-virus agent and method for treatment of viral infection Active AU2017220391B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023201883A AU2023201883B2 (en) 2016-02-19 2023-03-28 Anti-virus agent and method for treatment of viral infection

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2016900595 2016-02-19
AU2016900595A AU2016900595A0 (en) 2016-02-19 Method for treatment of cancer or viral infection
AU2016902715 2016-07-11
AU2016902715A AU2016902715A0 (en) 2016-07-11 Method for treatment of cancer or viral infection
PCT/AU2017/050139 WO2017139849A1 (en) 2016-02-19 2017-02-17 Anti-virus agent and method for treatment of viral infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023201883A Division AU2023201883B2 (en) 2016-02-19 2023-03-28 Anti-virus agent and method for treatment of viral infection

Publications (2)

Publication Number Publication Date
AU2017220391A1 AU2017220391A1 (en) 2018-05-17
AU2017220391B2 true AU2017220391B2 (en) 2023-01-19

Family

ID=59624666

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017220391A Active AU2017220391B2 (en) 2016-02-19 2017-02-17 Anti-virus agent and method for treatment of viral infection
AU2023201883A Active AU2023201883B2 (en) 2016-02-19 2023-03-28 Anti-virus agent and method for treatment of viral infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023201883A Active AU2023201883B2 (en) 2016-02-19 2023-03-28 Anti-virus agent and method for treatment of viral infection

Country Status (7)

Country Link
US (2) US11045491B2 (https=)
EP (1) EP3416656B1 (https=)
JP (1) JP6812436B2 (https=)
CN (1) CN108472311B (https=)
AU (2) AU2017220391B2 (https=)
ES (1) ES2867453T3 (https=)
WO (1) WO2017139849A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115397880B (zh) * 2020-01-31 2025-06-17 瑞克制药有限公司 用于制备生物活性共聚物的工艺
US20210330700A1 (en) * 2020-04-23 2021-10-28 Johnson & Johnson Consumer Inc. Methods and compositions for inhibiting influenza viruses using low molecular weight hydrophobically modified polymers and polyalkylene glycols
WO2025129262A1 (en) * 2023-12-21 2025-06-26 Gramele Industrial Holdings Pty Ltd Methods of ameliorating microbial growth

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059350A1 (en) * 2007-11-07 2009-05-14 Recce Pty Ltd Anti-microbial polymers and their compositions
WO2016077879A1 (en) * 2014-11-18 2016-05-26 Recce Limited Copolymer and method for treatment of bacterial infection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3278126D1 (en) * 1981-09-30 1988-03-31 Nat Res Dev Sustained release compositions
CN87108390A (zh) * 1986-12-23 1988-09-21 生物聚合物有限公司 抑制生物和杀生物的组合物
NZ222979A (en) 1986-12-23 1990-09-26 Biopolymers Ltd Polymeric biocidal or biostatic compounds and compositions
AUPN327695A0 (en) 1995-05-30 1995-06-22 Chemeq Pty. Limited Chemotherapeutic compositions
US6060571A (en) 1996-02-22 2000-05-09 Degussa Aktiengesellschaft Acrolein-releasing copolymers
EP0792895B1 (de) * 1996-02-22 2001-05-16 Degussa AG Acrolein freisetzende Copolymere
US6060235A (en) 1997-09-19 2000-05-09 Geltex Pharmaceuticals, Inc. Antiviral polymers comprising acid functional groups and hydrophobic groups
US7629002B2 (en) 2000-02-16 2009-12-08 Chemeq Ltd. Antimicrobial polymeric compositions and method of treatment using them
AU754178B2 (en) 2000-02-16 2002-11-07 Chemeq Ltd Antimicrobial polymeric compositions
CN1617733B (zh) * 2002-01-18 2010-04-07 凯米克有限公司 胃肠疾病的治疗方法和用于其中的聚合物组合物
AUPS327102A0 (en) * 2002-06-28 2002-07-18 Chemeq Ltd Method of treatment or prophylaxis of gastrointestinal diseases
BRPI0416298A (pt) * 2003-11-06 2007-01-23 Chemeq Ltd método para manufatura de poliacroleìna
EP2186521A1 (en) * 2008-11-14 2010-05-19 Mergemeier Steffen Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
AU2010100972A4 (en) * 2009-10-19 2010-10-07 Chemeq Ltd Topical antimicrobial compositions
WO2011047420A1 (en) * 2009-10-19 2011-04-28 Chemeq Ltd Cosmetic compositions
US20190202908A1 (en) * 2014-04-15 2019-07-04 President And Fellows Of Harvard College Bi-specific agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059350A1 (en) * 2007-11-07 2009-05-14 Recce Pty Ltd Anti-microbial polymers and their compositions
WO2016077879A1 (en) * 2014-11-18 2016-05-26 Recce Limited Copolymer and method for treatment of bacterial infection

Also Published As

Publication number Publication date
AU2023201883B2 (en) 2024-08-08
HK1254547A1 (zh) 2019-07-19
CN108472311B (zh) 2021-06-22
EP3416656A1 (en) 2018-12-26
WO2017139849A1 (en) 2017-08-24
US20210275573A1 (en) 2021-09-09
US20180338994A1 (en) 2018-11-29
US11045491B2 (en) 2021-06-29
AU2023201883A1 (en) 2023-05-04
CN108472311A (zh) 2018-08-31
EP3416656B1 (en) 2021-04-21
JP6812436B2 (ja) 2021-01-13
EP3416656A4 (en) 2019-11-13
AU2017220391A1 (en) 2018-05-17
ES2867453T3 (es) 2021-10-20
JP2019510731A (ja) 2019-04-18

Similar Documents

Publication Publication Date Title
AU2023201883B2 (en) Anti-virus agent and method for treatment of viral infection
IL300482B1 (en) Macrophage targeting drug conjugates
EP3220923B1 (en) Copolymer and method for treatment of bacterial infection
US20220401469A1 (en) Process for preparation of biologically active copolymer
HK1254547B (zh) 抗病毒剂和治疗病毒感染的方法
RU2172631C2 (ru) Индуктор интерферона пролонгированного действия
EP2186521A1 (en) Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
US20240150441A1 (en) Monoclonal antibodies against sars-cov-2 and variants
RU2845060C1 (ru) Нацеленные на макрофаги конъюгаты лекарственных средств
HK40103746A (zh) 共聚物和治疗细菌感染的方法
WO2007040426A1 (en) Antiviral agent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)